

**Amendments to the Claims:**

This listing of claims will replace all prior versions and listings of the claims in the application.

**Listing of Claims:**

1. (Currently Amended) A method for the treatment of retinal edema in an individual afflicted with retinal edema, comprising effecting an increase in the amount of an endostatin in ocular tissues of an individual afflicted with retinal edema to a retinal edema-inhibiting effective amount, wherein the increase is effected by a subretinal injection of an effective amount of a viral vector comprising an endostatin-encoding nucleic acid to the individual.

2. (Original) The method of claim 1 wherein the endostatin is a polypeptide with the amino acid sequence set forth in SEQ ID NO:1.

3. (Original) The method of claim 1, wherein the endostatin is a polypeptide fragment of the polypeptide with the amino acid sequence set forth in SEQ ID NO:1, a derivative of the polypeptide with the amino acid sequence set forth in SEQ ID NO:1, or a variant of the polypeptide with the amino acid sequence set forth in SEQ ID NO:1.

4-6. (Cancel)

7. (Withdrawn, Currently Amended) The method of claim 16, wherein the viral vector is ~~selected from the group consisting of an adeno-associated virus vector and a retrovirus.~~

8. (Withdrawn, Currently Amended) The method of claim 16, wherein the viral vector is an adenoviral vector.

9-21. (Cancel)

22. (Withdrawn, Original) The method of claim 8, wherein the vector is administered in an amount of from about  $10^8$  plaque forming units to about  $10^{14}$  plaque forming units.

23-26. (Cancel)

27. (Currently Amended) The method of claim 16, wherein the endostatin-encoding nucleic acid has the sequence set forth in SEQ ID NO:2.

28-30. (Cancel)

31. (Currently Amended) The method according to claim 16, wherein the viral vector is a lentiviral vector.

32-35. (Cancel)

36. (Original) The method of claim 31, wherein the lentiviral vector is a bovine immunodeficiency viral vector.

37-39. (Cancel)

40. (Currently Amended) The method of claim 16, wherein the increase is inducibly effected by the administration to the individual of a viral vector that can cause the production in the individual of an agent that will induce the expression of the endostatin-encoding nucleic acid.

41-48. (Cancel)

49. (New) The method of claim 1, wherein the viral vector is a retroviral vector.